{
    "2020-12-14": [
        [
            {
                "time": "",
                "original_text": "贝达药业（300558.SZ）：在研新药BPI-43487临床试验获批",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-43487",
                        "临床试验",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：在研新药BPI-43487获得临床试验批准通知书",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-43487",
                        "临床试验",
                        "批准通知书"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "贝达药业：在研新药BPI-43487临床试验获批",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-43487",
                        "临床试验",
                        "获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "研发日报丨恒瑞氟唑帕利胶囊、海思科环泊酚注射液获批上市",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "氟唑帕利胶囊",
                        "海思科",
                        "环泊酚注射液",
                        "获批上市"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "天风证券：创新药行业 十年十倍赛道下的巨头与新规",
                "features": {
                    "keywords": [
                        "天风证券",
                        "创新药",
                        "十年十倍",
                        "赛道",
                        "巨头",
                        "新规"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药生物行业周报：2021医药“春季躁动”有望提前到来 关注医药消费投资机会",
                "features": {
                    "keywords": [
                        "医药生物",
                        "周报",
                        "春季躁动",
                        "提前到来",
                        "医药消费",
                        "投资机会"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}